Preclinical and translational pharmacology of afucosylated anti‐CCR8 antibody for depletion of tumour‐infiltrating regulatory T cells
British Journal of Pharmacology · 2024-07 · 181 (13) · 2033-2052
DOI: 10.1111/bph.16326 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Pharmacology, online erschienen am 14.03.2024. Verfasst von Gautham Gampa und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Preclinical and Translational Pharmacokinetics and Pharmacodynamics, Genentech, Inc., South San Francisco, California, USA. Hauptthemen laut MEDLINE: Macaca fascicularis, T-Lymphocytes, Regulatory, Receptors, CCR8. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Genentech.
Abstract (Originalsprache)
Background and Purpose RO7502175 is an afucosylated antibody designed to eliminate C–C motif chemokine receptor 8 (CCR8) + Treg cells in the tumour microenvironment through enhanced antibody‐dependent cellular cytotoxicity (ADCC). Experimental Approach We report findings from preclinical studies characterizing pharmacology, pharmacokinetics (PK)/pharmacodynamics (PD) and safety profile of RO7502175 and discuss the translational PK/PD approach used to inform first‐in‐human (FiH) dosing strategy and clinical development in solid tumour indications. Key Results RO7502175 demonstrated selective ADCC against human CCR8 + Treg cells from dissociated tumours in vitro. In cynomolgus monkeys, RO7502175 exhibited a biphasic concentration–time profile consistent with immunoglobulin G1 (IgG1) antibodies, reduced CCR8 + Treg cells in the blood, induced minimal and transient cytokine secretion, and was well tolerated with a no‐observed‐adverse‐effect level (NOAEL) of 100 mg·kg −1 . Moreover, RO7502175 caused minimal cytokine release from peripheral blood mononuclear cells (PBMCs) in vitro. A quantitative model was developed to capture surrogate anti‐murine CCR8 antibody PK/PD and tumour dynamics in mice and RO7502175 PK/PD in cynomolgus monkeys. Subsequently, the model was used to project RO7502175 human PK and receptor occupancy (RO) in patients. Because traditional approaches resulted in a low FiH dose for this molecule, even with its superior preclinical safety profile, an integrated approach based on the totality of preclinical data and modelling insights was used for starting dose selection. Conclusion and Implications This work demonstrates a translational research strategy for collecting and utilizing relevant nonclinical data, developing a mechanistic PK/PD model and using a comprehensive approach to inform clinical study design for RO7502175.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Preclinical and Translational Pharmacokinetics and Pharmacodynamics, Genentech, Inc., South San Francisco, California, USA.
- Department of Bioanalytical Sciences, Genentech, Inc., South San Francisco, California, USA.
- Department of Safety Assessment, Genentech, Inc., South San Francisco, California, USA.
- Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, California, USA.
- Department of Early Clinical Development, Genentech, Inc., South San Francisco, California, USA.
- Department of Biochemical Cellular Pharmacology, Genentech, Inc., South San Francisco, California, USA.
ORCID-Profile: John Davies
Förderung
- Genentech
Zitieren
APA
Gampa, G., Spinosa, P., Getz, J., Zhong, Y., Halpern, W., Esen, E., Davies, J., Chou, C., Kwong, M., Wang, Y., Arenzana, T. L., Shivva, V., Huseni, M., Hsieh, R., Schartner, J., Koerber, J. T., Rutz, S., & Hosseini, I. (2024). Preclinical and translational pharmacology of afucosylated anti‐CCR8 antibody for depletion of tumour‐infiltrating regulatory T cells. British Journal of Pharmacology, 181(13), 2033-2052. https://doi.org/10.1111/bph.16326
Vancouver
Gampa G, Spinosa P, Getz J, Zhong Y, Halpern W, Esen E, et al. Preclinical and translational pharmacology of afucosylated anti‐CCR8 antibody for depletion of tumour‐infiltrating regulatory T cells. British Journal of Pharmacology. 2024;181(13):2033-2052. doi:10.1111/bph.16326
BibTeX
@article{Gampa2024,
author = {Gampa, Gautham and Spinosa, Phillip and Getz, Jennifer and Zhong, Yu and Halpern, Wendy and Esen, Emel and Davies, John and Chou, Cassie and Kwong, Mandy and Wang, Yingyun and Arenzana, Teresita L and Shivva, Vittal and Huseni, Mahrukh and Hsieh, Robert and Schartner, Jill and Koerber, James T and Rutz, Sascha and Hosseini, Iraj},
title = {Preclinical and translational pharmacology of afucosylated anti‐CCR8 antibody for depletion of tumour‐infiltrating regulatory T cells},
journal = {British Journal of Pharmacology},
year = {2024},
volume = {181},
number = {13},
pages = {2033--2052},
doi = {10.1111/bph.16326}
}
EUVIMED